Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 2c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $36 million versus the consensus estimate of $37.27 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Goldman Sachs Reinstates Erste Group Bank (EBS:AV) (EBKDY) at Buy
• JPMorgan Upgrades Wolters Kluwer NV (WKL:NA) (WTKWY) to Overweight